FDA Aims To Boost Transparency Through Earlier Release Of Panel Materials
This article was originally published in The Tan Sheet
FDA will post advisory committee briefing materials on its Web site at least two business days in advance of meetings, doubling the current lead time in an effort to enhance transparency, according to a Feb. 28 draft guidance
You may also be interested in...
FDA's Drug Safety and Risk Management Advisory Committee will be a tougher venue for drug sponsors during the next four years - long-time consumer advocate Sidney Wolfe recently was named a permanent committee member
Applications for Rx-to-OTC switches will continue to be reviewed in advisory committee meetings because they often meet FDA's reasons to seek an advisory panel's recommendation under a proposed guidance
FDA's draft guidance on the procedure for disclosing conflicts of interest will extend the agency's disclosure policy to cover all advisory committee members